All In Biotech

Drug Trial Radar · NCT07375524

A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome

Last checked: Nov 19, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Mar 1, 2026

Primary completion

Dec 31, 2027

Study completion Jun 30, 2028

Sponsor

Sponsor type
Industry
First posted
Jan 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with primary Sjögren's syndrome.

Conditions

  • Primary Sjögren Syndrome

Interventions

  • ESG206Drug

    ESG206 Low Dose administered by intravenous infusion

  • ESG206Drug

    ESG206 High Dose administered by intravenous infusion

  • PlaceboDrug

    Placebo administered by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in ESSDAI score compared with placebo.Time frame: Up to approximately 25 weeks

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking University Shougang Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • The Second Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • Hebei Petro China Central Hospital

    Langfang, Hebei, China

  • Changde First People's Hospital

    Changde, Hunan, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Zhuzhou Central Hospital

    Zhuzhou, Hunan, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • the Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Affiliated Hospital of Jining Medical University

    Jining, Shandong, China

  • Zaozhuang Municipal Hospital

    Zaozhuang, Shandong, China

  • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • Affiliated Hospital of North Sichuan Medical College

    Nanchong, Sichuan, China

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

  • Huzhou Third People's Hospital

    Huzhou, Zhejiang, China

  • Jinhua Municipal Central Hospital

    Jinhua, Zhejiang, China

  • Wenzhou People's Hospital

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.